Literature DB >> 32961375

Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.

Colin Flannelly1, Bryan E-Xin Tan2, Jian Liang Tan3, Colin M McHugh4, Chandrika Sanapala4, Tara Lagu5, Jane L Liesveld4, Omar Aljitawi4, Michael W Becker4, Jason H Mendler4, Heidi D Klepin6, Wendy Stock7, Tanya M Wildes8, Andrew Artz9, Navneet S Majhail10, Kah Poh Loh11.   

Abstract

Hematopoietic cell transplantation (HCT) is an effective treatment for many hematologic malignancies, and its utilization continues to rise. However, due to the difficult logistics and high cost of HCT, there are significant barriers to accessing the procedure; these barriers are likely greater for older patients. Although numerous factors may influence HCT access, no formal analysis has detailed the cumulative barriers that have been studied thus far. We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to better categorize the barriers to access and referral to HCT, with a focus on the subgroup of older patients. We searched for articles published in English from PubMed, Embase, Cumulative Index for Nursing and Allied Health, and Cochrane Central Register of Controlled Trials between the database inception and January 31, 2020. We selected articles that met the following inclusion criteria: (1) study design: qualitative, cross-sectional, observational cohort, or mixed-method study designs; (2) outcomes: barriers related to patient and physician access to HCT; and (3) population: adults aged ≥18 years with hematologic malignancies within the United States. Abstracts without full text were excluded. QUALSYST methodology was used to determine article quality. Data on the barriers to access and referral for HCT were extracted, along with other study characteristics. We summarized the findings using descriptive statistics. We included 26 of 3859 studies screened for inclusion criteria. Twenty studies were retrospective cohorts and 4 were cross-sectional. There was 1 prospective cohort study and 1 mixed-method study. Only 1 study was rated as high quality, and 16 were rated as fair. Seventeen studies analyzed age as a potential barrier to HCT referral and access, with 16 finding older age to be a barrier. Other consistent barriers to HCT referral and access included nonwhite race (n = 16/20 studies), insurance status (n = 13/14 studies), comorbidities (n = 10/11 studies), and lower socioeconomic status (n = 7/8 studies). High-quality studies are lacking related to HCT barriers. Older age and nonwhite race were consistently linked to reduced access to HCT. To produce a more just health care system, strategies to overcome these barriers for vulnerable populations should be prioritized. Examples include patient and physician education, as well as geriatric assessment guided care models that can be readily incorporated into clinical practice.
Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Age; Barriers; Hematopoietic cell transplantation; Race

Mesh:

Year:  2020        PMID: 32961375      PMCID: PMC7686105          DOI: 10.1016/j.bbmt.2020.09.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.609


  54 in total

1.  Patient housing barriers to hematopoietic cell transplantation: results from a mixed-methods study of transplant center social workers.

Authors:  Jaime M Preussler; Lih-Wen Mau; Navneet S Majhail; Margaret Bevans; Emilie Clancy; Carolyn Messner; Leslie Parran; Kate A Pederson; Stacy Stickney Ferguson; Kent Walters; Elizabeth A Murphy; Ellen M Denzen
Journal:  Support Care Cancer       Date:  2015-08-15       Impact factor: 3.603

2.  Barriers to Allogeneic Hematopoietic Stem Cell Transplantation for Human T Cell Lymphotropic Virus 1-Associated Adult T Cell Lymphoma-Leukemia in the United States: Experience from a Large Cohort in a Major Tertiary Center.

Authors:  Diego Adrianzen Herrera; Noah Kornblum; Ana Acuna-Villaorduna; R Alejandro Sica; Urvi Shah; Moya Butler; Nivetha Vishnuvardhan; Nishi Shah; Lizamarie Bachier-Rodriguez; Olga Derman; Aditi Shastri; Ioannis Mantzaris; Amit K Verma; Ira Braunschweig; Murali Janakiram
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-12       Impact factor: 5.742

3.  Factors affecting receipt of expensive cancer treatments and mortality: evidence from stem cell transplantation for leukemia and lymphoma.

Authors:  Jean M Mitchell; Elizabeth A Conklin
Journal:  Health Serv Res       Date:  2014-07-22       Impact factor: 3.402

4.  Hematopoietic stem cell transplantation among patients with leukemia of all ages in Texas.

Authors:  Jessica P Hwang; Tony P Lam; Deborah S Cohen; Michele L Donato; Jane M Geraci
Journal:  Cancer       Date:  2004-11-15       Impact factor: 6.860

5.  How generalizable are the SEER registries to the cancer populations of the USA?

Authors:  Tzy-Mey Kuo; Lee R Mobley
Journal:  Cancer Causes Control       Date:  2016-07-21       Impact factor: 2.506

6.  Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups.

Authors:  Dianne Pulte; Maria Theresa Redaniel; Lina Jansen; Hermann Brenner; Mona Jeffreys
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

7.  Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.

Authors:  Vijaya Raj Bhatt; Baojiang Chen; Bishal Gyawali; Stephanie J Lee
Journal:  Bone Marrow Transplant       Date:  2018-03-27       Impact factor: 5.483

8.  Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization.

Authors:  J Pidala; J Kim; M Schell; S J Lee; R Hillgruber; V Nye; E Ayala; M Alsina; B Betts; R Bookout; H F Fernandez; T Field; F L Locke; T Nishihori; J L Ochoa; L Perez; J Perkins; J Shapiro; C Tate; M Tomblyn; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2012-08-06       Impact factor: 5.483

9.  Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.

Authors:  Rebecca L Olin; Caitrin Fretham; Marcelo C Pasquini; Mukta Arora; Vijaya R Bhatt; Benjamin Derman; Sergio A Giralt; Li-Wen Huang; Thuy Koll; Sang Mee Lee; Richard J Lin; Linda Pang; Uday R Popat; Daniel J Weisdorf; Andrew Artz
Journal:  Blood Adv       Date:  2020-06-23

10.  Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults.

Authors:  Navneet S Majhail; Lih-Wen Mau; Pintip Chitphakdithai; Ellen M Denzen; Steven Joffe; Stephanie J Lee; Charles F LeMaistre; Fausto Loberiza; Susan K Parsons; Ramona Repaczki-Jones; Pam Robinett; J Douglas Rizzo; Elizabeth Murphy; Brent Logan; Jennifer Le-Rademacher
Journal:  Bone Marrow Transplant       Date:  2019-11-18       Impact factor: 5.483

View more
  6 in total

1.  Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation.

Authors:  Erica D Warlick; Celalettin Ustun; Astrid Andreescu; Anthony F Bonagura; Andrew Brunner; Abhinav B Chandra; James M Foran; Mark B Juckett; Tamila L Kindwall-Keller; Virginia M Klimek; Daniel F Pease; David P Steensma; Bryce M Waldman; Mary M Horowitz; Linda J Burns; Nandita Khera
Journal:  Cancer       Date:  2021-08-10       Impact factor: 6.860

Review 2.  Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics.

Authors:  Sanghee Hong; Navneet S Majhail
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Allogeneic hematopoietic cell transplantation for older patients.

Authors:  Richard J Lin; Andrew S Artz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma.

Authors:  Pashna N Munshi; Yue Chen; Kwang W Ahn; Farrukh T Awan; Amanda Cashen; Geoffrey Shouse; Mazyar Shadman; Paul Shaughnessy; Joanna Zurko; Frederick L Locke; Aaron M Goodman; Jose C Villaboas Bisneto; Craig Sauter; Mohamad A Kharfan-Dabaja; Gabrielle Meyers; Samantha Jaglowski; Alex Herrera; Mehdi Hamadani
Journal:  Transplant Cell Ther       Date:  2022-05-21

5.  Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis.

Authors:  Joseph E Maakaron; Mei-Jie Zhang; Karen Chen; Sunil Abhyankar; Vijaya Raj Bhatt; Saurabh Chhabra; Najla El Jurdi; Sherif S Farag; Fiona He; Mark Juckett; Marcos de Lima; Navneet Majhail; Marjolein van der Poel; Ayman Saad; Bipin Savani; Celalettin Ustun; Edmund K Waller; Mark Litzow; Partow Kebriaei; Christopher S Hourigan; Wael Saber; Daniel Weisdorf
Journal:  Bone Marrow Transplant       Date:  2022-04-02       Impact factor: 5.174

Review 6.  How old is too old for a transplant?

Authors:  Daniel Weisdorf
Journal:  Best Pract Res Clin Haematol       Date:  2021-01-12       Impact factor: 3.020

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.